.png){kind=icon}
返回
B
Byung‐Wan Lee
Yonsei University
53H指数
408论文数
1.8W被引数
收录论文 193
发表时间
.png){kind=icon}
Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical TrialHD-6277（一种新型G蛋白偶联受体40激动剂）在2型糖尿病受试者中的疗效与安全性：一项双盲、随机、安慰剂对照、平行组、多中心Ⅱ期临床试验.png)
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial在三联口服联合治疗控制不佳的2型糖尿病患者中，增加第四种口服降糖药与二甲双胍剂量递增的疗效和安全性 (努力): 一项为期24周的随机，开放标签，多中心试验
PREAI
分享收藏Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial吡格列酮、恩格列净和格列美脲作为三线药物在用二甲双胍和DPP-4抑制剂控制不佳的2型糖尿病患者中的疗效与安全性：一项多中心、4期随机对照试验
PREAI
分享收藏Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial噻唑烷二酮与钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病中治疗代谢功能障碍相关脂肪性肝病的协同效益：一项为期24周、开放标签、随机对照试验.png)
BMC MEDICINE
OAAI
BMC MEDICINEIF8.3
OAAI分享收藏